Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review - PubMed (original) (raw)
Review
. 2020 Aug 25;324(8):782-793.
doi: 10.1001/jama.2020.12839.
Affiliations
- PMID: 32648899
- DOI: 10.1001/jama.2020.12839
Review
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review
W Joost Wiersinga et al. JAMA. 2020.
Abstract
Importance: The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.
Observations: SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, presymptomatic, and symptomatic carriers. The average time from exposure to symptom onset is 5 days, and 97.5% of people who develop symptoms do so within 11.5 days. The most common symptoms are fever, dry cough, and shortness of breath. Radiographic and laboratory abnormalities, such as lymphopenia and elevated lactate dehydrogenase, are common, but nonspecific. Diagnosis is made by detection of SARS-CoV-2 via reverse transcription polymerase chain reaction testing, although false-negative test results may occur in up to 20% to 67% of patients; however, this is dependent on the quality and timing of testing. Manifestations of COVID-19 include asymptomatic carriers and fulminant disease characterized by sepsis and acute respiratory failure. Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. More than 75% of patients hospitalized with COVID-19 require supplemental oxygen. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care (21.6% vs 24.6%; age-adjusted rate ratio, 0.83 [95% CI, 0.74-0.92]) and that remdesivir improves time to recovery (hospital discharge or no supplemental oxygen requirement) from 15 to 11 days. In a randomized trial of 103 patients with COVID-19, convalescent plasma did not shorten time to recovery. Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulants. The case-fatality rate for COVID-19 varies markedly by age, ranging from 0.3 deaths per 1000 cases among patients aged 5 to 17 years to 304.9 deaths per 1000 cases among patients aged 85 years or older in the US. Among patients hospitalized in the intensive care unit, the case fatality is up to 40%. At least 120 SARS-CoV-2 vaccines are under development. Until an effective vaccine is available, the primary methods to reduce spread are face masks, social distancing, and contact tracing. Monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies.
Conclusions and relevance: As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. Many aspects of transmission, infection, and treatment remain unclear. Advances in prevention and effective management of COVID-19 will require basic and clinical investigation and public health and clinical interventions.
Similar articles
- Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J. Emadi A, et al. Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article. - COVID-19 in Children: Clinical Approach and Management.
Sankar J, Dhochak N, Kabra SK, Lodha R. Sankar J, et al. Indian J Pediatr. 2020 Jun;87(6):433-442. doi: 10.1007/s12098-020-03292-1. Epub 2020 Apr 27. Indian J Pediatr. 2020. PMID: 32338347 Free PMC article. Review. - Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K, Chakraborty A, Sur S. Hosoki K, et al. J Allergy Clin Immunol. 2020 Aug;146(2):285-299. doi: 10.1016/j.jaci.2020.05.033. Epub 2020 Jul 2. J Allergy Clin Immunol. 2020. PMID: 32624257 Free PMC article. Review. - Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P, Zhao MY. Zhang XY, et al. Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6. Infect Dis Poverty. 2020. PMID: 32690096 Free PMC article. Review. - COVID-19 pandemic: A review based on current evidence.
Mahalmani VM, Mahendru D, Semwal A, Kaur S, Kaur H, Sarma P, Prakash A, Medhi B. Mahalmani VM, et al. Indian J Pharmacol. 2020 Mar-Apr;52(2):117-129. doi: 10.4103/ijp.IJP_310_20. Epub 2020 Jun 3. Indian J Pharmacol. 2020. PMID: 32565599 Free PMC article. Review.
Cited by
- The Effect of Change Position on Cardiac Function Patterns on Patients with COVID-19 Diagnosis: A Clinical Trial Study.
Akbari M, Jafarimanesh H, Nasiri A, Rostami H, Mahdavi Z, Fayazi N. Akbari M, et al. Curr Health Sci J. 2024 Apr-Jun;50(2):223-231. doi: 10.12865/CHSJ.50.02.07. Epub 2024 Jun 30. Curr Health Sci J. 2024. PMID: 39371069 Free PMC article. - Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report.
Zhang YX, Tang J, Zhu D, Wu CY, Liang ML, Huang YT. Zhang YX, et al. World J Radiol. 2024 Sep 28;16(9):489-496. doi: 10.4329/wjr.v16.i9.489. World J Radiol. 2024. PMID: 39355387 Free PMC article. - Comparison of Standard and Prone-Position Electrocardiograms in COVID-19 Patients With Pulmonary Complications: Correlations and Implications.
Makarawate P, Chimtim K, Mitsungnern T, Phungoen P, Imoun S, Mootsikapun P, Tangpaisarn T, Kotruchin P. Makarawate P, et al. Clin Cardiol. 2024 Oct;47(10):e70024. doi: 10.1002/clc.70024. Clin Cardiol. 2024. PMID: 39344374 Free PMC article. - Targeting Cytokines: Evaluating the Potential of Mesenchymal Stem Cell Derived Extracellular Vesicles in the Management of COVID-19.
Schultz IC, Dos Santos Pereira Andrade AC, Dubuc I, Laroche A, Allaeys I, Doré E, Bertrand N, Vallières L, Fradette J, Flamand L, Wink MR, Boilard E. Schultz IC, et al. Stem Cell Rev Rep. 2024 Sep 28. doi: 10.1007/s12015-024-10794-4. Online ahead of print. Stem Cell Rev Rep. 2024. PMID: 39340739 - The predictive significance of uric acid to high density lipoprotein- cholesterol ratio and uric acid for the severity and mortality of coronavirus disease-19.
Rohani-Rasaf M, Ghavidel F, Hosseini H, Teimouri M. Rohani-Rasaf M, et al. BMC Res Notes. 2024 Sep 27;17(1):277. doi: 10.1186/s13104-024-06807-7. BMC Res Notes. 2024. PMID: 39334249 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous